CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$28.50 +10.47% (+$2.70)
1M +31.76%
Market Cap $8.06B
P/E Ratio 76.63x
Div. Yield -
ROE 18.77%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive P/E 76.63x
P/B 13.61x
EV/EBITDA 45.27x
Growth
100 /100
Growing Rev. growth 46.46%
EPS growth N/A
Book val. growth N/A
Profitability
79 /100
Strong Gross margin 69.66%
FCF margin 14.80%
Net margin 10.62%
Quality
79 /100
Excellent ROIC 14.69%
Asset turnover 0.80x
ROE 18.77%
Debt
78 /100
Low Debt/Equity 0.76x
Net debt/EBITDA -1.38x
Current ratio 5.53x
Stability
41 /100
Moderate Beta 0.68x
Profitable years 0
Rev. volatility 41.46%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Nadchodzące wydarzenia
04 LIS
Earnings
Upcoming earnings report